Eli Lilly's latest marketcap:
As of 08/02/2025, Eli Lilly's market capitalization has reached $684.37 B. According to our data, Eli Lilly is the 15th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 684.37 B |
| Revenue (ttm) | 49 B |
| Net Income (ttm) | 11.11 B |
| Shares Out | 897.74 M |
| EPS (ttm) | 12.29 |
| Forward PE | 30.30 |
| Ex-Dividend Date | 08/15/2025 |
| Earnings Date | 08/07/2025 |
Eli Lilly's yearly market capitalization.
| Date | Market Cap($) | Change (%) | Global Rank |
|---|---|---|---|
| 08/02/2025 | $684.37 B | -1.71% | 15 |
| 12/31/2024 | $732.87 B | 32.44% | 12 |
| 12/29/2023 | $553.37 B | 59.19% | 10 |
| 12/30/2022 | $347.61 B | 31.56% | 19 |
| 12/31/2021 | $264.23 B | 63.6% | 36 |
| 12/31/2020 | $161.51 B | 27.99% | 67 |
| 12/31/2019 | $126.19 B | 2.94% | 78 |
| 12/31/2018 | $122.58 B | 31.81% | 57 |
| 12/29/2017 | $93 B | 14.54% | 103 |
| 12/30/2016 | $81.2 B | -13.04% | 92 |
Company Profile
About Eli Lilly and Company
Eli Lilly and Company is a global pharmaceutical leader dedicated to discovering, developing, and marketing innovative human healthcare solutions. Founded in 1876 and headquartered in Indianapolis, Indiana, the company operates across the United States, Europe, China, Japan, and other international markets.
Key Product Offerings
Diabetes & Obesity Treatments:
- Basaglar, Humalog, Humulin, and insulin-based therapies
- Jardiance, Mounjaro, and Trulicity for type 2 diabetes
- Zepbound for obesity management
Oncology Products:
- Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio
Other Therapeutic Areas:
- Olumiant (rheumatoid arthritis, atopic dermatitis, COVID-19)
- Taltz (plaque psoriasis, psoriatic arthritis)
- Omvoh (ulcerative colitis)
- Cymbalta (depressive disorder, chronic pain)
- Ebglyss (severe atopic dermatitis)
- Emgality (migraine prevention)
Strategic Collaborations
Eli Lilly partners with leading organizations to advance medical innovation, including:
- Incyte Corporation
- Boehringer Ingelheim Pharmaceuticals
- F. Hoffmann-La Roche Ltd and Genentech, Inc.
- AbCellera Biologics Inc. and Verge Genomics
- AdvanCell (targeted cancer therapies)
- Chugai Pharmaceutical Co., Ltd.
Frequently Asked Questions
-
What is Eli Lilly's (LLY) current market cap?As of 08/02/2025, Eli Lilly (including the parent company, if applicable) has an estimated market capitalization of $684.37 B USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Eli Lilly (LLY) rank globally by market cap?Eli Lilly global market capitalization ranking is approximately 15 as of 08/02/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.